gene

GAN

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about GAN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

54Connections
15Hypotheses
0Analyses
38Outgoing
16Incoming
20Experiments
0Debates

Summary

GAN is a gene implicated in neurodegeneration research. Key relationships include: therapeutic target, activates, inhibits. Associated with Fibrosis, Ms, Neurodegeneration. Connected to 22 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info
Gene SymbolGAN
Full NameGigaxonin
Chromosome16q24.2
Functionis a key component of the ubiquitin-proteasome system, functioning as a substrate adaptor for the Cullin-3 (CUL3)-RING ligase complex
Molecular Weight65 kDa
Amino Acids597 aa
Exons11
PathwaysBlood-Brain Barrier, Immune Response, Nf-Κb, Tgf-Β, blood-brain barrier
UniProt ID[Q9Y2H5](https://www.uniprot.org/uniprot/Q9Y2H5)
Ensembl IDENSG00000150433
OMIM605379
GeneCardsGAN
Human Protein AtlasGAN
N-terminal BTB domainMediates homodimerization and interactions with Cullin-3 E3 ubiquitin ligases[@geyer2012]
Central BACK domainInvolved in substrate recognition
Associated DiseasesGiant Axonal Neuropathy
InteractionsAND, NEURODEGENERATION, NEURODEGENERATIVE DISEASES, NEURODEGENERATIVE DISORDERS, NF-ΚB, SYNUCLEINOPATHY
KG Connections54 knowledge graph edges
DatabasesGeneCardsNCBI GeneHPASTRING

Wiki Pages (3)

Knowledge base pages for this entity

Canonical Page

GAN Gene

gene · 1368 words

GAN Protein

protein · 870 words

Gigaxonin (GAN) Protein

protein · 604 words

Pathway Diagram

graph TD
    GAN["GAN"]
    Fibrosis{"Fibrosis"}
    GAN -->|"activates"| Fibrosis
    Neurodegeneration{"Neurodegeneration"}
    GAN -->|"therapeutic target"| Neurodegeneration
    Ms{"Ms"}
    GAN -->|"therapeutic target"| Ms
    Synucleinopathy{"Synucleinopathy"}
    GAN -->|"therapeutic target"| Synucleinopathy
    Tgf__(["Tgf-Beta"])
    GAN -->|"activates"| Tgf__
    Immune_Response(["Immune Response"])
    GAN -->|"therapeutic target"| Immune_Response
    Nf__b(["Nf-Kappab"])
    GAN -->|"therapeutic target"| Nf__b
    Blood_Brain_Barrier(["Blood-Brain Barrier"])
    GAN -->|"therapeutic target"| Blood_Brain_Barrier
    neurodegeneration["neurodegeneration"]
    GAN -->|"implicated in"| neurodegeneration
    TRKB["TRKB"]
    TRKB -->|"inhibits"| GAN
    TNF["TNF"]
    TNF -->|"therapeutic target"| GAN
    SYNUCLEINOPATHY["SYNUCLEINOPATHY"]
    SYNUCLEINOPATHY -->|"therapeutic target"| GAN
    NEURODEGENERATION["NEURODEGENERATION"]
    NEURODEGENERATION -->|"therapeutic target"| GAN
    NEURODEGENERATIVE_DISEASES["NEURODEGENERATIVE DISEASES"]
    NEURODEGENERATIVE_DISEASES -->|"therapeutic target"| GAN
    NF__B["NF-KappaB"]
    NF__B -->|"therapeutic target"| GAN
    AND["AND"]
    AND -->|"therapeutic target"| GAN
    TNF__["TNF-Alpha"]
    TNF__ -->|"therapeutic target"| GAN
    style GAN fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (38)

TargetRelationTypeStr
axonal degenerationregulatesprocess0.70
Giant Axonal Neuropathycausesdisease0.70
Fibrosisactivatesdisease0.65
Neurodegenerationtherapeutic_targetdisease0.65
Mstherapeutic_targetdisease0.65

Incoming (16)

SourceRelationTypeStr
ANDtherapeutic_targetgene0.60
TNFtherapeutic_targetgene0.60
SYNUCLEINOPATHYtherapeutic_targetgene0.60
NEURODEGENERATIONtherapeutic_targetgene0.60
NEURODEGENERATIVE DISEASEStherapeutic_targetgene0.60

Targeting Hypotheses (15)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
TBK1-OPTN-NDP52 Phospho-Cascade Coordinates Multi-Organelle 0.772 neurodegeneration How do different organelle-specific auto
Phase-Separated Organelle Targeting 0.729 neurodegeneration Microglia-astrocyte crosstalk amplificat
TFEB/TFE3 Parallel Activation Drives Coordinated Organelle C 0.727 neurodegeneration How do different organelle-specific auto
TFAM overexpression creates mitochondrial donor-recipient gr 0.725 neurodegeneration Mitochondrial transfer between astrocyte
Ganglioside Rebalancing Therapy 0.690 neurodegeneration Lipid raft composition changes in synapt
LDLR Ligand-Binding Domain A Fusion for Receptor-Mediated Tr 0.650 neurodegeneration Blood-brain barrier antibody transport m
p62 Liquid-Liquid Phase Separation Nucleates Cross-Organelle 0.649 neurodegeneration How do different organelle-specific auto
APOE-TREM2 Ligand Availability Dysfunction in Neurodegenerat 0.649 neurodegeneration Gene expression changes in aging mouse b
Mitochondrial ROS from complex I and cardiolipin instability 0.640 neurodegeneration What mechanisms drive the self-amplifyin
Ganglioside-rich extracellular vesicles preserve alpha-synuc 0.582 neurodegeneration Which specific CSF molecular components
VPS34 Complex I Subunit Heterogeneity Dictates Organelle-Spe 0.571 neurodegeneration How do different organelle-specific auto
A pre-organized hairpin or loop in lncRNA-0021 creates a hig 0.540 molecular neurobiology How does lncRNA-0021 achieve sequence-sp
Metabolic Accumulation (Ammonia/Manganese) Triggers IBA1 Dow 0.517 neuroinflammation What causes IBA1 low/negative microglia
Tumor-derived extracellular vesicles as TREM2 ligands 0.490 neurodegeneration Does the cancer-cystatin-C-TREM2 pathway
GM1 Ganglioside Reduction via ST3GAL5 Activation to Block Aβ 0.465 lipidomics Lipid metabolism dysregulation in Alzhei

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (20)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
G3BP1-mediated stress granule assembly via liquid-liquid phase separat exploratory 0.900 0.00 eukaryotic cells proposed N/A
IRI-AKI mouse model with mtROS inhibition validation ischemic acute kidney injury 0.900 0.00 IRI-AKI mice proposed N/A
mtROS effects on TFAM and mtDNA in HK2 cells exploratory acute kidney injury 0.900 0.00 HK2 cells proposed N/A
G3BP1 intrinsically disordered region analysis and phosphorylation eff exploratory 0.850 0.00 in vitro protein analysis syst proposed N/A
TFAM knockdown functional analysis exploratory acute kidney injury 0.850 0.00 HK2 cells proposed N/A
G3BP1-binding factor cooperativity in stress granule network regulatio exploratory 0.800 0.00 cell culture systems with prot proposed N/A
TFAM and mtDNA analysis in AKI patients clinical acute kidney injury 0.800 0.00 human patients proposed N/A
Proposed experiment from debate on TDP-43 undergoes liquid-liquid phas falsification Neurodegeneration 0.400 0.50 cell_line proposed $80,000
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FTD validation ALS 0.400 0.50 human proposed $2,730,000
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study clinical ALS 0.400 0.50 human proposed $6,550,000
Pre-Symptomatic Detection and Intervention Timing in Genetic Prion Dis validation ALS 0.400 0.50 human proposed $2,280,000
Stress Granule Dysfunction Validation in Parkinson's Disease clinical Parkinson's Disease 0.400 0.50 human proposed $5,460,000
Experiment Validation: In vitro ThT Assay validation Alzheimer's Disease 0.400 0.50 cell_line proposed $160,000
s:** - Test MCU overexpression specifically in layer II neurons in hea falsification Neurodegeneration 0.400 0.50 mouse proposed $200,000
Proposed experiment from debate on Mitochondrial transfer between astr falsification Neurodegeneration 0.400 0.50 cell_line proposed $80,000
Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec validation Neurodegeneration 0.400 0.50 cell_line proposed $160,000
Exercise-BDNF-Mitophagy Biomarker Study in PD clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000
Ferroptosis Validation in Parkinson's Disease clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000
GLP-1 Agonist Neuroprotection Mechanism in PD clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's Disease clinical Parkinson's Disease 0.400 0.50 human proposed $7,100,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Stress granule homeostasis is modulated by TRIM21-mediated ubiquitination of G3B [PMID:36692217] Yang C, Wang Z, Kang Y, Yi Q, Wang T, Ba Autophagy 2023 3
G3BP1 Is a Tunable Switch that Triggers Phase Separation to Assemble Stress Gran [PMID:32302571] Yang P, Mathieu C, Kolaitis RM, Zhang P, Cell 2020 3
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic t [PMID:32048886] Yao RQ, Ren C, Xia ZF, Yao YM Autophagy 2021 2
Hypoxia-driven phase separation of the PABP1/eIF4B complex forms stress granules [PMID:41780839] Lin Z, Gao Y, Zhang Q, Yang S, Chen Y, D Cancer Lett 2026 1
Melatonin attenuates sepsis-induced acute kidney injury by promoting mitophagy t [PMID:37651673] Deng Z, He M, Hu H, Zhang W, Zhang Y, Ge Autophagy 2024 1
TFAM is an autophagy receptor that limits inflammation by binding to cytoplasmic [PMID:38783142] Liu H, Zhen C, Xie J, Luo Z, Zeng L, Zha Nat Cell Biol 2024 1
Membrane Atg8ylation, stress granule formation, and MTOR regulation during lysos [PMID:36394332] Jia J, Wang F, Bhujabal Z, Peters R, Mud Autophagy 2023 1
Mitochondrial-derived damage-associated molecular patterns amplify neuroinflamma [PMID:35233090] Lin MM, Liu N, Qin ZH, Wang Y Acta Pharmacol Sin 2022 1
Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic [PMID:33408785] Zhao M, Wang Y, Li L, Liu S, Wang C, Yua Theranostics 2021 1
Mitochondrial DNA copy number in human disease: the more the better? [PMID:33314045] Filograna R, Mennuni M, Alsina D, Larsso FEBS Lett 2021 1
Mitochondrial DNA stress triggers autophagy-dependent ferroptotic death. [PMID:32186434] Li C, Zhang Y, Liu J, Kang R, Klionsky D Autophagy 2021 1
Butyrate extends health and lifespan in mice with mitochondrial deficiency. [PMID:41826362] ["Gaband\u00e9-Rodr\u00edguez E", "G\u00 Nature communications 2026 0
Vav-iCre-Mediated Deletion of TFAM Is Not Recoverable and Is Consistent with Emb [PMID:41898789] ["Ghosh R", "Shakur E", "Yousefzadeh M"] Genes 2026 0
NRIP1 co-activates nuclear translocated FOXO3 to upregulate TFAM expression and [PMID:41888517] ["Zha Y", "Huang H", "Liu Y", "Wan M", " Cell death discovery 2026 0
Implications of virus-induced stress granules in tauopathies. [PMID:41673769] Sharma S, Vandenakker A, Cortés-Pérez C, Translational neurodegeneratio 2026 0
miR-137-5p-Loaded Milk-Derived Small Extracellular Vesicles Modulate Oxidative S [PMID:41754992] ["G\u00f6n\u00fcll\u00fc S", "Ayd\u0131n Pharmaceutics 2026 0
Ginseng stem and leaf saponins attenuates pulmonary fibrosis by regulating TFAM- [PMID:41911987] Chen Y, Hu L, Fu Q, Chen H, Jiang Z, Li Journal of ethnopharmacology 2026 0
AMPK promotes TFEB transcriptional activity through dephosphorylation at both MT [PMID:41661247] Negoita F, Fraguas Bringas C, Hellberg K Autophagy 2026 0
Implications of virus-induced stress granules in tauopathies. [PMID:41673769] Sharma S, Vandenakker A, Cortés-Pérez C, Transl Neurodegener 2026 0
Pharmacological modulation of stress granules via G3BP1/2: A pathway to treat ca [PMID:41924133] Yang J, Gao F Front Pharmacol 2026 0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning GAN in their description or question text

LDLR Ligand-Binding Domain A Fusion for Receptor-Mediated Transcytosis

Score: 0.650 · neurodegeneration · 2026-04-22

**Molecular Mechanism and Rationale** The low-density lipoprotein receptor (LDLR) represents a promising gateway for th

p62 Liquid-Liquid Phase Separation Nucleates Cross-Organelle Cargo for Coordinat

Score: 0.649 · neurodegeneration · 2026-04-21

## Mechanistic Overview p62 Liquid-Liquid Phase Separation Nucleates Cross-Organelle Cargo for Coordinated Autophagy sta

APOE-TREM2 Ligand Availability Dysfunction in Neurodegeneration

Score: 0.649 · neurodegeneration · 2026-04-17

**Molecular Mechanism and Rationale** The APOE-TREM2 ligand availability dysfunction hypothesis centers on the critical

Mitochondrial ROS from complex I and cardiolipin instability forms a local organ

Score: 0.640 · neurodegeneration · 2026-04-25

Electron leak at complex I and destabilized inner-membrane architecture generate superoxide and lipid oxidation that dam

Ganglioside-rich extracellular vesicles preserve alpha-synuclein fibril conforma

Score: 0.582 · neurodegeneration · 2026-04-25

Membrane-derived cofactors in extracellular vesicles maintain polymorph fidelity and templating competence.

VPS34 Complex I Subunit Heterogeneity Dictates Organelle-Specific vs. Bulk Autop

Score: 0.571 · neurodegeneration · 2026-04-21

## Mechanistic Overview VPS34 Complex I Subunit Heterogeneity Dictates Organelle-Specific vs. Bulk Autophagy starts from

A pre-organized hairpin or loop in lncRNA-0021 creates a high-affinity docking s

Score: 0.540 · molecular neurobiology · 2026-04-25

lncRNA-0021 may contain a pre-folded structural element that lowers the entropic cost of binding and presents the miR-63

Metabolic Accumulation (Ammonia/Manganese) Triggers IBA1 Downregulation via NRF2

Score: 0.517 · neuroinflammation · 2026-04-21

## Mechanistic Overview Metabolic Accumulation (Ammonia/Manganese) Triggers IBA1 Downregulation via NRF2 starts from the

Tumor-derived extracellular vesicles as TREM2 ligands

Score: 0.490 · neurodegeneration · 2026-04-25

Tumor extracellular vesicles carrying phosphatidylserine activate microglia via TREM2, enhancing neuroprotective functio

GM1 Ganglioside Reduction via ST3GAL5 Activation to Block Aβ Oligomerization See

Score: 0.465 · lipidomics · 2026-04-25

GM1 Ganglioside Reduction via ST3GAL5 Activation to Block Aβ Oligomerization Seeds